FDC LTD. Q4 FY26 Results

Summary

FDC Limited announced robust consolidated financial results for Q4 FY26 and the full fiscal year ending March 31, 2026. The company's revenue from operations for Q4 FY26 increased by 18.9% year-on-year to ₹585 crores, while the full-year revenue reached ₹2,171 crores, growing by 3.0%. Profit After Tax saw a significant jump of 167.4% in Q4 FY26 to ₹103 crores and improved by 5.5% to ₹281 crores for FY26. Enhanced operational efficiencies contributed to a notable improvement in EBITDA margins, which stood at 18.2% for Q4 FY26. Key growth drivers included strong performance across all three business segments, with the Export Formulations and API businesses showing substantial growth, and the US business overcoming challenges to deliver strong results.

Key Highlights

1. 1

   FDC Limited reported a strong Q4 FY26 consolidated revenue from operations of ₹585 crores, marking a robust year-on-year growth of 18.9%.

2. 2

   For the full fiscal year 2026, consolidated revenue from operations stood at ₹2,171 crores, increasing by 3.0% compared to the previous year.

3. 3

   Profit After Tax (PAT) for Q4 FY26 surged by an impressive 167.4% year-on-year to ₹103 crores, while for FY26, PAT grew by 5.5% to ₹281 crores.

4. 4

   EBITDA for Q4 FY26 significantly grew by 97.0% to ₹106 crores, with EBITDA margins improving to 18.2% from 11.0% in Q4 FY25, driven by enhanced operational efficiencies.

5. 5

   The Export Formulations business demonstrated exceptional growth in Q4 FY26, soaring by 99.3% year-on-year, contributing 15% to consolidated sales.

6. 6

   The US business delivered strong performance in Q4 FY26, with revenue from supplies reflecting a year-on-year growth of 165.1%, and overall US business revenue grew 46.9% year-on-year for FY26.

7. 7

   During Q4 FY26, the company received U.S. FDA approval for Fluconazole Tablets USP 50mg, 100mg, 150mg and 200mg.